NBS 10

Drug Profile

NBS 10

Alternative Names: AMR-001; CLBS 10; NBS10

Latest Information Update: 28 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amorcyte
  • Developer Caladrius Biosciences
  • Class Stem cell therapies
  • Mechanism of Action Angiogenesis inducing agents; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Brain injuries
  • Discontinued Myocardial infarction

Most Recent Events

  • 15 Mar 2016 Caladrius out-licenses CD34 ischemic repair technnology to SPS Cardio LLC
  • 18 Dec 2015 NBS 10 is available for licensing as of 18 Dec 2015. http://www.caladrius.com/
  • 08 Jun 2015 Phase-II development for Myocardial infarction is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top